CHTOUROU; Abdessatar Sami

Patent Applications and Registrations

Patent applications and USPTO patent grants for CHTOUROU; Abdessatar Sami.The latest application filed is for "combination of ant-cd303 and anti-amhrii antibodies".

Company Profile

7.7.14

CHTOUROU; Abdessatar Sami - Elancourt FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combination Of Ant-cd303 And Anti-amhrii Antibodies App 20200095326 - CHTOUROU; Abdessatar Sami ; et al.	2020-03-26
Factor X Variants App 20190338269 - CHTOUROU; Abdessatar Sami ; et al.	2019-11-07
Combination Of Anti-cd303 And Anti-her2 Antibodies App 20190330369 - CHTOUROU; Abdessatar Sami ; et al.	2019-10-31
Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units Grant 10,364,425 - Chtourou , et al.	2019-07-30
Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units Grant 10,344,272 - Chtourou , et al. July 9, 2	2019-07-09
New Use Of An Anti-cd303 Transmembrane Protein Antibody App 20190002567 - CHTOUROU; Abdessatar Sami ; et al.	2019-01-03
Method for purifying transgenic factor VII/VIIA Grant 9,982,247 - Bataille , et al. May 29, 2	2018-05-29
Composition Enriched In Anti-a And/or Anti-b Polyclonal Immunoglobulins For Use In The Treatment Of Autoimmune Diseases Or Polycythemia App 20180142036 - CHTOUROU; Abdessatar Sami	2018-05-24
Biological Glue And Use Thereof As A Medicament App 20170296694 - CHTOUROU; Abdessatar Sami ; et al.	2017-10-19
Oral Composition Of Anti-tnf Alpha Antibodies App 20170121402 - Chtourou; Abdessatar Sami	2017-05-04
Method For Inactivating A Prion Protein App 20160089422 - Chtourou; Abdessatar Sami ; et al.	2016-03-31
Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A Grant 8,802,620 - Chtourou , et al. August 12, 2	2014-08-12
Recombinant Or Transgenic Factor Vii Composition, Each Factor Vii Molecule Having Two N-glycosylation Sites With Defined Glycan Units App 20140093491 - Chtourou; Abdessatar Sami ; et al.	2014-04-03
Recombinant Or Transgenic Factor Vii Compound Having A Majority Of Glycan, Biantennary, Bisialylated And Non-fucosylated Forms App 20130189244 - Chtourou; Abdessatar Sami ; et al.	2013-07-25
Demannosylated Recombinant Factor Viii [[vii]] For The Treatment Of Patients With Haemophilia A App 20100197578 - Chtourou; Abdessatar Sami ; et al.	2010-08-05
Recombinant Or Transgenic Factor Vii Composition, Each Factor Vii Molecule Having Two N-glycosylation Sites With Defined Glycan Units App 20090311239 - Chtourou; Abdessatar Sami ; et al.	2009-12-17
Recombinant Or Transgenic Factor Vii Compound Having A Majority Of Glycan, Biantennary, Bisialylated And Non-fucosylated Forms App 20090239788 - Chtourou; Abdessatar Sami ; et al.	2009-09-24
Method for preparing human immunoglobulin concentrates for therapeutic use Grant 7,186,410 - Chtourou , et al. March 6, 2	2007-03-06
Method for preparing human immunoglobulin concentrates for therapeutic use App 20040132979 - Chtourou, Abdessatar Sami ; et al.	2004-07-08

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.